Compare WBX & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WBX | VERU |
|---|---|---|
| Founded | 2015 | 1971 |
| Country | Spain | United States |
| Employees | 696 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 40.9M |
| IPO Year | N/A | 1996 |
| Metric | WBX | VERU |
|---|---|---|
| Price | $3.23 | $2.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $4.75 | ★ $22.50 |
| AVG Volume (30 Days) | 19.0K | ★ 46.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | $18.10 | N/A |
| Revenue Next Year | $94.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $0.36 |
| 52 Week High | $7.83 | $4.59 |
| Indicator | WBX | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 61.85 | 47.53 |
| Support Level | $2.84 | $2.13 |
| Resistance Level | $3.26 | $2.67 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 91.86 | 21.85 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.